Jiegu Wan Market

Key data points: Market size in 2027 = $10.1 billion and 2035 = $13.8 billion, growth forecast = 4.1% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in jiegu wan market to 2035 by type (water-honey pills and large honey pills), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Jiegu Wan Market The future of the global jiegu wan market looks promising with opportunities in the hospital and clinic markets. The global jiegu wan market is expected to reach an estimated $13.8 billion by 2035 from $10.1 billion in 2027 with a CAGR of 4.1% from 2027 to 2035. The major drivers for this market are the increasing demand for bone healing remedies, the rising adoption of traditional Chinese medicine, and the growing use in fracture pain management. • Lucintel forecasts that, within the type category, large honey pills is expected to witness higher growth over the forecast period due to higher potency and slower-release honey pills. • Within the application category, hospital is expected to witness higher growth over the forecast period due to rising hospital-based practices of traditional remedies for bone healing. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to greater acceptance of traditional medicine and improved access to health care services. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Jiegu Wan Market Lucintel has identified different trends regarding Fufang Luobuma Granules. During the forecast period, different types of Granules will be used for supporting evidence based herbal medicinal practices. Additionally, tougher quality standards will be introduced for the pharmaceutical industry, and consequently an increase in the demand for herbal medicinal products will be observed. Growth in the industry will be mostly influenced by the company's ability to establish evidence based formulations, and adhere to required quality and standards. • Clinical Standardization: Stricter guidelines for batch traceability will be introduced. Safety data of the product will help establish the product in the market. It is expected that in next 3-5 years, formulary and hospital based practice products will be accepted. • Preventive Cardiovascular Care: Rising awareness about cardiovascular health, and pressure will increase the demand for herbal medicinal products. In the long term, (2025 onwards) its expected that national policies will address long term management of hypertension. As a result, Fufang Luobuma Granules will be used for management of hypertension, and other associated conditions. • Digital Pharmacy: Rising use of Internet for medical consultation and digitization of pharmacies will help customers buy medicinal products from their homes. Pharmacy based products will be marketed by pharmacists, using Internet. Digital products will be prioritising for customer's choice and repetitive purchases. • Modernized Formulations: Anticipating consumer interest in more controlled and consistent methods of preparation, companies will launch new products featuring company-developed technology for improved extraction and granulation, as well as packaging in individual doses. Products launched between now and 2027 will charge a premium if they incorporate traditional Chinese Medicine (TCM) into other, more conventional, methods of formulation. Premium pricing may also allow for wider, non-hospital use. • Supply-chain Quality Control: Differentiated raw material sourcing and domestic cultivation have reduced the variance in raw materials used in traditional Chinese Medicine products. In the meantime, the Chinese government continues to enhance its oversight of traditional Chinese Medicine. Depending on their supply-chain partners, companies may have stronger, more stable business outlooks with respect to pricing, product availability and liability. The market for Luobuma Granules will continue to grow, and companies integrating innovation throughout their value-chains to enhance product quality and safety will find greater success. This will also help alleviate price-based competition among companies supplying TCM products to hospitals. The greatest opportunity exists with companies creating innovative TCM products for use in outpatient, chronic care. Recent Developments in the Jiegu Wan Market Wan market activity is anticipated in 2025-2027, for improvement of quality and evidence based practice for Traditional Chinese Medicine (TCM). Lucintel has analyzed and anticipated that the market will shift from unstructured and retail medicine to structured and recommended medicine by a pharmacist. • Shift in Regulations: In February 2025, the Chinese Food and Drug Administration (CFDA) revised the norm for the registration of Traditional Chinese Medicine (TCM). This revised norm increases the requirement and expectation from TCM manufacturers for documentation and consistency in a batch of medicine. This creates a barrier for the informal manufacturers of TCM. • Change in Channel for Sale of Medicine: From 2025, certain provinces of China adopted Volume-based procurement policy for medicines. As a part of this policy, a set of Chinese Patent medicines were evaluated for centralized procurement. This reduced the price of Chinese Patent medicines and made them available in hospitals. • Structural Changes in Manufacturing: Several large manufacturers of TCM invested in various integrated systems for automation, traceability and quality in 2025. These systems and changes made in the TCM manufacturing processes are expected to create a positive impact in winning larger, high value contracts. • Digital Distribution of Prescription Medication: Major pharmaceutical companies launched prescription-based online services in March 2025, allowing licensed pharmacies to provide medication through hospital and clinical office referrals. For Jiegu Wan, this development creates the opportunity to expand its customer base beyond the traditional pharmacies that sell TCM medications, and to stop relying on individual practitioners and unregulated website for distribution. • Use of Evidence-based Medicine: There were several studies to evaluate the efficacy of different therapies for the repair and reconstruction of the musculoskeletal system and other related conditions, published during 2025. More clinical studies can help pharmaceutical companies support their pricing and policy decisions to include their products in hospital formularies, and to obtain product registrations in other countries. Jiegu Wan and similar products target a segment of the traditional Chinese medicine market that is large enough to ensure good sales for the next 5-6 years. There is potential for further growth through the use of compliant manufacturing practices, and by focusing on the distribution to hospitals and other large customers. Companies that employ practices to ensure quality and differentiate themselves will succeed, while others will fail due to price competition. Strategic Growth Opportunities in the Jiegu Wan Market The Fufang Luobuma Granule market is expected to develop in view of increasing hypertension screening, preferences for plant-based add-ons, and industry’s advancements in evidence bundle creation. Between 2024 and 2026, more stringent quality standards and regulations would lead to the removal of illegal/informal products from the market, and provide an opportunity for compliant products. Lucintel is of the view that the market would provide attractive opportunities in the future, if products are clinically positioned, and forward/ahead of market innovations. • Light-touch Regulatory Approach for Evidence-based Hypertension Support: Companies can conduct real-world studies for evidence bundling for the product, and build an evidence base to support blood pressure management. As of May 2025, China estimated that 330 million adults suffered from hypertension. • Clinical Partnerships: Fufang Luobuma Granules can be marketed to support and enhance traditional therapies, especially in rural and underserved areas of China where basic medical insurance is available. • Premium Standardized Formulations: The introduction of stricter alkaloid limits, combined with extract fingerprinting and greater batch-to-batch consistency, result in higher-valued products. The implementation of the 2025 Chinese Pharmacopoeia (CP) in 2025 will mandate the improvement of medicinal product documentation. Until now, the main competition in the market has been based on prices. In the future, competition will also depend on the safety and quality of the products and the reputation of the manufacturers. • Digital Adherence Services: Once customers buy a product, the services provided help them remain customers. The use of the internet for health and medical purposes in China has been on the rise. Digital services have the potential to improve customer retention and help product companies better understand how consumers use their products. In the next 5 years, there will be little to no change on the formulation of products, giving companies time to analyze consumer behavior. • Regional Export Channels: Medicinal herbs are widely accepted in the countries located in South East Asia, and the region has a growing geriatric population. Some countries have provisions to allow the sale of traditional medicines through pharmacies, and companies can enter these markets quickly through the medicinal herb distributors. Focus will be on the highest potential segments of traditional medicines. Companies that efficiently and effectively integrate traditional medicines into the healthcare system will have an edge. Some traditional medicines can be used to manage chronic conditions. The traditional medicines should be safe, affordable and have evidence to support their use. Jiegu Wan Market Drivers and Challenges Jiegu Wan market growth is shaped by customer demand, technological progress, regulatory developments, sustainability priorities, and manufacturing economics. Rising interest in traditional therapies supports adoption, while quality control, clinical validation, and market-access requirements create obstacles. Lucintel’s market perspective emphasizes how these interacting forces will determine competition, investment, and product development. The factors responsible for driving the jiegu wan market include:- • Customer Demand: Growing interest in traditional Chinese medicine and non-invasive approaches to bone, joint, and soft-tissue recovery is expanding consumer attention toward Jiegu Wan. In January 2025, the World Health Organization continued implementing its traditional medicine strategy, supporting broader integration of evidence-based traditional therapies. Over the next three to five years, aging populations, sports injuries, and demand for complementary care are likely to sustain market interest, particularly where consumers seek affordable products that complement conventional treatment. • Technology Improvements: Better extraction, fingerprinting, stability testing, and digital traceability are improving the consistency of multi-herb formulations. In March 2025, analytical laboratories increasingly used high-resolution liquid chromatography and mass spectrometry to identify numerous botanical constituents in traditional medicines. Over the next three to five years, these technologies should strengthen quality assurance, reduce adulteration concerns, and help manufacturers provide clearer evidence regarding composition, dosage, and batch-to-batch consistency. • Regulatory Support: Formal recognition of traditional medicine and clearer registration pathways can improve distribution and consumer confidence. In February 2025, India’s Union Budget maintained substantial public support for the AYUSH sector, with the Ministry of Ayush receiving approximately ₹3,992 crore for fiscal year 2025–26. Over the next three to five years, regulatory clarification, pharmacopoeial standards, and supervised clinical use could encourage legitimate commercialization while separating compliant products from unverified claims. • Sustainability: Sustainable sourcing of botanical ingredients is becoming more important as manufacturers face pressure to protect biodiversity and demonstrate responsible supply chains. In April 2025, the Convention on Biological Diversity continued advancing benefit-sharing discussions affecting genetic resources and associated traditional knowledge. Over the next three to five years, certified cultivation, traceable procurement, and lower-waste extraction will influence supplier selection, brand reputation, and long-term availability of ingredients used in Jiegu Wan formulations. • Manufacturing Efficiency: Automated dosing, standardized granulation, improved packaging, and contract manufacturing are helping producers lower costs and increase output. In June 2025, pharmaceutical manufacturers worldwide continued expanding continuous and digitally monitored production systems to improve process control. Over the next three to five years, manufacturing efficiency should support more reliable pricing, larger retail coverage, stronger export readiness, and consistent product quality, especially for companies able to meet pharmaceutical-grade documentation requirements. The challenges facing this market include: • Clinical Evidence Limitations: Limited large-scale, independently replicated clinical studies can restrict acceptance among physicians, hospitals, and regulated pharmacies. In May 2025, clinical-trial registration platforms continued to show that many traditional medicine studies remained small or regionally concentrated, often involving fewer than 500 participants. Over the next three to five years, insufficient evidence may slow reimbursement, constrain medical recommendations, and make it difficult for manufacturers to substantiate therapeutic claims across international markets. • Quality and Safety Risks: Variations in herb species, cultivation conditions, processing methods, contamination, and counterfeit products can undermine consumer trust. In July 2025, regulators continued emphasizing permissible limits for heavy metals, pesticides, and microbial contamination in botanical products. Over the next three to five years, stricter testing will increase compliance costs, but failure to meet these standards could result in recalls, import restrictions, reputational damage, and reduced confidence in the jiegu wan market. • Market Access and Competition: Jiegu Wan faces competition from analgesics, physical therapy, supplements, and other traditional formulations, while different countries apply inconsistent rules to herbal medicines. In September 2025, many international markets still classified comparable botanical products differently, including as medicines, supplements, or traditional remedies. Over the next three to five years, fragmented registration requirements, limited consumer education, and strong substitute products may increase marketing costs and delay international expansion. The jiegu wan market has meaningful growth potential because consumer demand, analytical innovation, sustainability, regulatory development, and efficient manufacturing are improving its commercial foundation. However, limited clinical evidence, quality risks, and fragmented market-access rules may restrict rapid expansion. Success will depend on standardized ingredients, credible research, transparent labeling, sustainable sourcing, and compliance with local regulations. Manufacturers that combine traditional knowledge with modern validation and controlled production will be best positioned to build trust. Overall, the market is likely to expand gradually, with stronger opportunities in regulated channels and regions where traditional medicine is increasingly integrated into broader healthcare systems. List of Jiegu Wan Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies jiegu wan market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the jiegu wan market companies profiled in this report include- • Inner Mongolia Datang Pharmaceutical Co., Ltd. • Beijing Tongrentang Technology Development Co., Ltd. • Hebei Wansui Pharmaceutical Co., Ltd. • Beijing Zhibaicao Pharmaceutical Co., Ltd. • Jilin Huangzhihua Pharmaceutical Co., Ltd. Jiegu Wan Market by Segment The study includes a forecast for the global jiegu wan market by type, application, and region. Jiegu Wan Market by Type [Value ($B) from 2019 to 2035]: • Water-honey Pills • Large Honey Pills Jiegu Wan Market by Application [Value ($B) from 2019 to 2035]: • Hospital • Clinic • Others Jiegu Wan Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Jiegu Wan Market The development of the Fufang Luobuma Granules market has been more associated with the formalization of the traditional medicine industry and the manufacture of the product, as opposed to the launch of the product. According to Lucintel’s report, in the period of 2025-2027, relaxations in policies would permit production and marketing of standardized botanical products. The report also states that in this period, a good number of countries would put in place policies to improve the quality of herbal products. • United States: In 2025 (January), the FDA reported that it had registered 29,000 Food (including Botanical) Products facilities, and manufacturers. Currently, the FDA has not put in place comprehensive policies to govern the importation, marketing and manufacture of Fufang Luobuma and other botanical products. So, it is expected that in the period 2025-2030, Fufang Luobuma products will be imported and marketed as dietary supplements. However, if they are imported and marketed as a drug or in a special (restricted) channel, then it may occur in this period. • China: In May 2025, the 2025 edition of the Chinese Pharmacopoeia, which sets standards for traditional Chinese medicines (including 7,244), was implemented throughout China. Local authorities also implements controls on the Traditional Chinese Medicines. Given the above standards and specifications, a given botanical product may be available in hospitals, or not available in the retail market. • Germany: The same laws applied to all EU nations allow traditional herbal medicinal products once product quality has been established. The EU herbal monograph update process is ongoing, and the EMA plans to complete 3 monographs by 2025. This creates a system to integrate traditional Chinese Medicinal Products (TCMP) into the pharmacy and practitioner distribution system; however, it places an administrative and economic burden on the distribution of Chinese herbal products in granular form. • India: Per the Ministry of Ayush, 2025 (April 2025) reported 8,000 plus licensed manufacturers of Ayurvedic, Siddha and Unani products and homoeopathic products. Continuous improvements by industry in quality and safety of products helped strengthen the credibility of Indian systems of medicine. The large number of licensed producers may provide the TCMP industry a base for local processing of TCMPs and customized/private label production if the products comply with local standards. • Japan: The Pharmaceuticals and Medical Devices Agency (PMDA) reviewed 148 Kampo products in 2025 (April 2025). The establishment of reimbursement for these products facilitates similar products to gain clinical acceptance. However, the application of the country’s stringent standards for evaluation of herbal products will likely impede the entry of competing products into the market. Features of the Global Jiegu Wan Market Market Size Estimates: jiegu wan market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: jiegu wan market size by type, application, and region in terms of value ($B). Regional Analysis: jiegu wan market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the jiegu wan market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the jiegu wan market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the jiegu wan market by type (water-honey pills and large honey pills), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?